| Literature DB >> 28565814 |
Lu Liang1, Jin-Bo Liu1, Fu-Qin Chen1, Jing Zhao2, Xiao-Li Zhang1.
Abstract
The present study reported on an unusual case of refractory hypotension induced by Sheehan syndrome with pituitary crisis and explored the causes and treatment of hypotension in hypopiptuitarism. Refractory hypotension is a rare and severe complication of longstanding hypopituitarism induced by Sheehan syndrome with pituitary crisis. A 48-year-old Chinese woman with pituitary crisis due to Sheehan syndrome developed refractory hypotension and received longstanding vasopressor blood pressure support and hormone replacement therapy. Besides normalized blood pressure, echocardiography over 3 months revealed partial reversibility of her cardiac function with hormone replacement therapy. Consistent numerous studies reviewed, hormone replacement therapy may improve cardiac function in patients with cardiomyopathy linked to Sheehan syndrome. A retrospective study of 77 cases with hypopituitarism encountered at Qilu Hospital of Shandong University (Jinan, China) was also performed and the incidence rate of hypotension was analyzed, revealing that the present case was the first of refractory hypotension induced by Sheehan syndrome with pituitary crisis at this institution in 16 years.Entities:
Keywords: Sheehan syndrome; hormone replacement therapy; hypopituitarism; pituitary crisis; refractory hypotension
Year: 2017 PMID: 28565814 PMCID: PMC5443209 DOI: 10.3892/etm.2017.4188
Source DB: PubMed Journal: Exp Ther Med ISSN: 1792-0981 Impact factor: 2.447
Endocrine levels at baseline and follow-up.
| During hospital | After discharge | |||
|---|---|---|---|---|
| Parameter | Baseline | Day 21 | 3 months | Normal range |
| Free triiodothyronine (pmol/l) | <1.54 | 2.40 | 4.12 | 2.63–5.63 |
| Free thyroxine (pmol/l) | <5.15 | 10.41 | 27.06 | 9.01–19.01 |
| Thyroid-stimulating hormone (µIU/ml) | 0.36 | 0.26 | 0.04 | 0.35–4.35 |
| Cortisol (µg/dl) | 1.3 | 8.7–22.7 | ||
| Adrenocorticotrophic hormone (pg/ml) | 1.6 | 4.7–48.7 | ||
| Luteinizing hormone (mIU/ml) | 0.55 | 7.7–58.7 | ||
| Follicle-stimulating hormone (mIU/ml) | 0.34 | 25.8–134.8 | ||
| Estradiol (pg/ml) | 12.17 | 10-39.5 | ||
| Prolactin (ng/ml) | 0.31 | 3.4–24.4 | ||
| Insulin-like growth factor-1 (ng/ml) | 5.2 | 60–350 | ||
| Growth hormone (ng/ml) | 0.027 | 0.01–5.01 | ||
Biochemical parameters at baseline and follow-up.
| During hospital | After discharge | |||||||
|---|---|---|---|---|---|---|---|---|
| Factors | Day 1 | Day 5 | Day 8 | Day 15 | Day 17 | Day 25 | 1 month | Normal range |
| White blood cells (x109/l) | 7.75 | 15.61 | 13.99 | 10.87 | 9.40 | 6.60 | 6.92 | 3.5–9.5 |
| Neutrophils (%) | 74.1 | 93.7 | 93.9 | 91.1 | 89.8 | 78.2 | 75.6 | 40–75 |
| Red blood cells (x1012/l) | 3.43 | 3.24 | 4.31 | 3.74 | 3.62 | 3.55 | 3.42 | 3.8–5.8 |
| Hemoglobin (g/dl) | 103 | 101 | 137 | 117 | 112 | 110 | 108 | 115–150 |
| Platelets (x109/l) | 209 | 118 | 121 | 175 | 193 | 172 | 224 | 125–350 |
| Alanine transaminase (U/l) | 39 | 308 | 356 | 53 | 42 | 18 | 13 | 7–40 |
| Aspartate transaminase (U/l) | 68 | 399 | 297 | 44 | 41 | 19 | 18 | 13–35 |
| Total protein (g/l) | 72.0 | 46.0 | − | 47.6 | 48.1 | 50.6 | 65.7 | 60–85 |
| Albumin (g/l) | 45.0 | 30.4 | 28.8 | 32.6 | 30.7 | 32.9 | 43.2 | 40–55 |
| Blood urea nitrogen (mmol/l) | 13.3 | 8.9 | 10.0 | 11.4 | 10.9 | 14.1 | 11.1 | 2.3–7.3 |
| Creatinine (µmol/l) | 119 | 125 | 129 | 121 | 114 | 99 | 99 | 53–97 |
| Natrium (mmol/l) | 136 | 144 | 143 | 144 | 143 | 139 | 141 | 137–147 |
| Potassium (mmol/l) | 2.60 | 3.85 | 3.78 | 3.78 | 2.57 | 4.96 | 3.07 | 3.5–5.5 |
| Fasting blood glucose (mmol/l) | 4.70 | 9.15 | – | 8.27 | – | 6.80 | 4.43 | 3.9–6.9 |
| Cholesterol (mmol/l) | 4.18 | – | – | – | – | – | 5.03 | 2.80–6.80 |
| Triglyceride (mmol/l) | 1.5 | – | – | – | – | – | 0.64 | 0.30–1.30 |
| LDL-C (mmol/l) | 2.45 | – | – | – | – | – | 2.95 | 1.00–3.00 |
| HDL-C (mmol/l) | 0.83 | – | – | – | – | – | 1.78 | 0.80–2.80 |
LDL-C, Low density lipoprotein cholesterin; HDL-C, high density lipoprotein cholesterin.
Indexes for cardiac function at baseline and follow-up.
| During hospital | After discharge | ||||||
|---|---|---|---|---|---|---|---|
| Factor | Day 1 | Day 5 | Day 17 | Day 25 | 1 month | 3 months | Normal range |
| Cardiac enzymes | |||||||
| Troponin-I (ng/ml) | 0.01 | 0.23 | 0.11 | 0.05 | 0.02 | – | 0-0.06 |
| CK-MB (ng/ml) | 8.0 | 4.7 | 4.6 | 2.1 | 2.2 | – | 0.3–4.3 |
| Nt-proBNP (pg/ml) | 548 | – | – | – | – | – | <125 |
| Electrocardiogram | |||||||
| Heart rate (beats/min) | 40 | 111 | 63 | 65 | 65 | 77 | 60–100 |
| PR interval | 200 | 130 | 196 | 160 | 196 | 190 | 120–200 |
| QRS duration (msec) | 78 | 61 | 83 | 68 | 80 | 78 | <120 |
| T wave | Flat | Flat | Flat | Flat | Flat | Normal | Normal |
| QT/QTc (msec) | 600/490 | 292/358 | 362/402 | 180/225 | 494/405 | 352/384 | Variable/350–440 |
| Low voltage | Limb leads | Limb leads | Limb leads | Limb leads | Limb leads | None | None |
| Echocardiography | |||||||
| LA dimension (mm) | 40 | – | – | 35 | – | 34 | <35 |
| RV dimension (mm) | 30 | – | – | 26 | – | 23 | <25 |
| LVEF (%) | 30 | – | – | 55 | – | 64 | >50 |
| LV motion | Abnormal diastolic hypokinesis | – | – | Abnormal diastolic filling | – | Abnormal diastolic filling | Normal |
| Tricuspid regurgitation | Severe-moderate | – | – | Moderate | – | Mild | Normal |
| Pericardial effusion | Medium amount | – | – | Medium amount | – | Small amount | None |
CK, creatine kinase; BNP, B-type natriuretic peptide; LVEF, left ventricle ejection fraction; LA, left atrium.
Figure 1.Blood pressure levels (mmHg) in the patient over the course of the treatment. SP, systolic blood pressure; DP, diastolic blood pressure; d, day(s).